Article
Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication by targeting…
medRxiv · 2021 · Chaves, O. A.; Sacramento, C. Q.; Fintelman-Rodrigues, N.; Temerozo, J. R.; Pereira-Dutra, F.; Mizurini, D. M.; Monteiro, R. Q.; Vazquez, L.; Bozza, P. T.; Castro-Faria-Neto, H. C.; Souza, T. M. L.
Key facts
| Title | Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication by targeting its major protease in a non-competitive way |
|---|---|
| First author | Chaves, O. A.; Sacramento, C. Q.; Fintelman-Rodrigues, N.; Temerozo, J. R.; Pereira-Dutra, F.; Mizurini, D. M.; Monteiro, R. Q.; Vazquez, L.; Bozza, P. T.; Castro-Faria-Neto, H. C.; Souza, T. M. L. |
| Journal | medRxiv |
| Published | Sep 26, 2021 |
| DOI | 10.1101/2021.09.23.461605 |
| Devices mentioned | K870938 |
| Product codes mentioned | KIS |
At a glance
- 1–9 FDA submissions mentioned
- 1–9 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1